Skip to content

Author

D. S. Tan

We have 3 of 69 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Genomic and transcriptomic landscape of spread through air spaces in stage 1 lung adenocarcinoma.

INTRODUCTION Spread through air spaces (STAS) is an adverse histologic feature in early-stage lung adenocarcinoma (LUAD) incorporated into the ninth edition TNM staging. Despite its clinical significance, the molecular features underlying STAS in stage 1 LUAD remain incompletely characterised. METHODS Patients with s...

S. Saw, Meng-Yuan Pang, C. Patteri et al. · 0 citations
Review Sep 2026

Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies.

Recent advances in NSCLC with established alterations are summarized, including EGFR, ALK, ROS1, KRAS, BRAF, RET, HER2, MET, and NTRK, and emerging targets are discussed, and emerging targets, such as NRG1 fusions, MTAP loss, and SMARCA4 deficiency are discussed.

L. Hendriks, Jessica J. Lin, D. S. Tan et al. · 2 citations
Review Aug 2026

AI-based augmentation of oncology clinical trials.

It is argued that achieving the potential of AI in oncology clinical trials will require rigorous prospective validation, harmonized regulatory standards, and coordination among clinicians, trialists, regulators, industry and patients.

Andrea Villa, A. Eadie, David Synnott et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.